Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

VolitionRx

MCap

USD76m

Last close

USD0.81

▲ 0.14 (20.90%)

Canyon Resources

MCap

AUD262m

Last close

AUD0.19

▲ 0.02 (12.12%)

Immix Biopharma

MCap

USD51m

Last close

USD1.82

▲ 0.12 (7.06%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

OpGen: Edison Open House Healthcare 2022

OpGen: Edison Open House Healthcare 2022

OpGen — 5 videos in collection

More on this equity

OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

• Tell us about OpGen’s focus on and approach to antimicrobial resistance.
• Please describe your licensing strategy for Ares Genetics.
• How large do you anticipate the unmet need in the genomic sequencing market to be?
• Which milestones should investors focus on in the coming year?

< Previous

Next >

You may also be interested in these:

Healthcare

20.12.22

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare

01.07.21

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free